KBC Group’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-10,154
| Closed | -$147K | – | 1856 |
|
|
2026
Q1 | $147K | Hold |
10,154
| – | – | ﹤0.01% | 1104 |
|
|
2025
Q4 | $145K | Hold |
10,154
| – | – | ﹤0.01% | 1060 |
|
|
2025
Q3 | $80K | Hold |
10,154
| – | – | ﹤0.01% | 1395 |
|
|
2025
Q2 | $58K | Hold |
10,154
| – | – | ﹤0.01% | 1533 |
|
|
2025
Q1 | $83K | Hold |
10,154
| – | – | ﹤0.01% | 1586 |
|
|
2024
Q4 | $96K | Buy |
10,154
+3,120
| +44% | +$32.4K | ﹤0.01% | 1587 |
|
|
2024
Q3 | $75K | Buy |
7,034
+204
| +3% | +$2.22K | ﹤0.01% | 1476 |
|
|
2024
Q2 | $68K | Buy |
6,830
+1,806
| +36% | +$18.5K | ﹤0.01% | 1432 |
|
|
2024
Q1 | $59K | Hold |
5,024
| – | – | ﹤0.01% | 1452 |
|
|
2023
Q4 | $71K | Hold |
5,024
| – | – | ﹤0.01% | 1281 |
|
|
2023
Q3 | $61K | Buy |
+5,024
| New | +$64.8K | ﹤0.01% | 1302 |
|
|
2019
Q4 | – | Sell |
-6,860
| Closed | -$55K | – | 1515 |
|
|
2019
Q3 | $55K | Buy |
6,860
+6,240
| +1,006% | +$67.7K | ﹤0.01% | 1383 |
|
|
2019
Q2 | $8K | Hold |
620
| – | – | ﹤0.01% | 1442 |
|
|
2019
Q1 | $8K | Hold |
620
| – | – | ﹤0.01% | 1401 |
|
|
2018
Q4 | $6K | Hold |
620
| – | – | ﹤0.01% | 1298 |
|
|
2018
Q3 | $7K | Hold |
620
| – | – | ﹤0.01% | 1383 |
|
|
2018
Q2 | $10K | Hold |
620
| – | – | ﹤0.01% | 1281 |
|
|
2018
Q1 | $9K | Hold |
620
| – | – | ﹤0.01% | 1264 |
|
|
2017
Q4 | $9K | Buy |
+620
| New | +$8.52K | ﹤0.01% | 1248 |
|
Other funds holding FOLD
KBC Group's FOLD Position: Q2 2026 in Review
KBC Group sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 10,154 shares — an estimated $147K sold.
KBC Group first reported a position in FOLD in Q4 2017 and held it in 19 quarters. The position peaked at $147K in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- KBC Group reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- KBC Group sold 10,154 Amicus Therapeutics shares in Q2 2026, an estimated $147K.
- KBC Group first reported a position in Amicus Therapeutics in Q4 2017 and held it in 19 quarters.
- KBC Group's Amicus Therapeutics position peaked at $147K in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.